These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34579268)

  • 1. Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report.
    Lijeskić O; Klun I; Stamenov Djaković M; Gligorić N; Štajner T; Srbljanović J; Djurković-Djaković O
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study.
    Stoma I; Korsak K; Voropaev E; Osipkina O; Kovalev A
    Heliyon; 2023 Nov; 9(11):e21877. PubMed ID: 38027828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 Vaccines Six Months after the Second Dose: A Longitudinal Prospective Study.
    Petrović V; Vuković V; Patić A; Marković M; Ristić M
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia.
    Petrović V; Vuković V; Patić A; Marković M; Ristić M
    PLoS One; 2022; 17(2):e0263468. PubMed ID: 35108321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco.
    Ezzikouri S; Tajudeen R; Majidi H; Redwane S; Aqillouch S; Abdulaziz M; Aragaw M; Papa Fallah M; Sembuche S; Batcho S; Kabwe P; Gonese E; Laazaazia O; Elmessaoudi-Idrissi M; Meziane N; Ainahi A; Sarih M; Ogwell Ouma AE; Maaroufi A
    Sci Rep; 2024 Apr; 14(1):7817. PubMed ID: 38570577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial.
    Batmunkh T; Moore KA; Thomson H; Altangerel B; Amraa O; Avaa N; Batbayar L; Batsukh K; Bright K; Burentogtokh T; Ha Do LA; Dorj G; Hart JD; Javkhlantugs K; Jigjidsuren S; Justice F; Li S; Licciardi PV; Mashbaatar K; Mazarakis N; Neal EFG; Nguyen CD; Ochirbat B; Tsolmon B; Tuya A; Surenjav U; von Mollendorf C; Mulholland K
    Lancet Reg Health West Pac; 2024 Jan; 42():100953. PubMed ID: 38357398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
    Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm.
    Anvari E; Ghamar Talepoor A; Eshkevar Vakili M; Karimi N; Ataollahi M; Najafi G; Kabelitz D; Ahmadi I; Kalantar K
    Iran J Immunol; 2022 Sep; 19(3):321-329. PubMed ID: 36190385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia.
    Batmunkh B; Otgonbayar D; Shaarii S; Khaidav N; Shagdarsuren OE; Boldbaatar G; Danzan NE; Dashtseren M; Unurjargal T; Dashtseren I; Dagvasumberel M; Jagdagsuren D; Bayandorj O; Biziya B; Surenjid S; Togoo K; Bat-Erdene A; Narmandakh Z; Choijilsuren G; Batmunkh U; Soodoi C; Boldbaatar EA; Byambatsogt G; Byambaa O; Deleg Z; Enebish G; Chuluunbaatar B; Zulmunkh G; Tsolmon B; Gunchin B; Chimeddorj B; Dambadarjaa D; Sandag T
    PLoS One; 2023; 18(12):e0295167. PubMed ID: 38064430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
    Mallah SI; Alawadhi A; Jawad J; Wasif P; Alsaffar B; Alalawi E; Mohamed AM; Butler AE; Alalawi B; Qayed D; Almahari SA; Mubarak A; Mubarak A; Saeed S; Humaidan A; Kumar N; Atkin S; Alqahtani M
    Vaccine; 2023 Mar; 41(12):1925-1933. PubMed ID: 36725431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
    Vályi-Nagy I; Matula Z; Gönczi M; Tasnády S; Bekő G; Réti M; Ajzner É; Uher F
    Geroscience; 2021 Oct; 43(5):2321-2331. PubMed ID: 34633612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mix-and-match COVID-19 vaccines trigger high antibody response after the third dose vaccine in Moroccan health care workers.
    Amellal H; Assaid N; Akarid K; Maaroufi A; Ezzikouri S; Sarih M
    Vaccine X; 2023 Aug; 14():100288. PubMed ID: 37008956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study.
    Al-Rifai RH; Alhosani F; Abuyadek R; Atef S; Donnelly JG; Leinberger-Jabari A; Ahmed LA; Altrabulsi B; Alatoom A; Alsuwaidi AR; AbdelWareth L
    Front Med (Lausanne); 2022; 9():1092646. PubMed ID: 36703898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy.
    Matula Z; Gönczi M; Bekő G; Kádár B; Ajzner É; Uher F; Vályi-Nagy I
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina.
    Eliçabe RJ; Distel MN; Jofré BL; Leporati M; Silva JE; Arias JL; Gorlino CV; Funes SC; Velazquez M; Vitale P; Davicino RC; Di Genaro MS
    Vaccine; 2023 Jan; 41(2):476-485. PubMed ID: 36481109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
    Rearte A; Castelli JM; Rearte R; Fuentes N; Pennini V; Pesce M; Barbeira PB; Iummato LE; Laurora M; Bartolomeu ML; Galligani G; Del Valle Juarez M; Giovacchini CM; Santoro A; Esperatti M; Tarragona S; Vizzotti C
    Lancet; 2022 Mar; 399(10331):1254-1264. PubMed ID: 35303473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged ≥60 Years in Vojvodina, Serbia.
    Petrović V; Vuković V; Marković M; Ristić M
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody responses to mRNA versus non-mRNA COVID vaccines among the Mongolian population.
    Sereejav E; Sandagdorj A; Bazarjav P; Ganbold S; Enkhtuvshin A; Tsedenbal N; Namuuntsetseg B; Chimedregzen K; Badarch D; Otgonbayar D; Artbazar B; Enebish O; Tsevegmid E; Baigude H; Batzorig U; Batmunkh B; Jantsansengee B; Tserendorj C; Dorjderem B; Tsolmon B; Ganbold T
    IJID Reg; 2023 Sep; 8():1-8. PubMed ID: 37309454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Vaccination in Preventing COVID-19: A Community Study Comparing Four Vaccines.
    Kokić Z; Kon P; Djurković-Djaković O
    Vaccines (Basel); 2023 Feb; 11(3):. PubMed ID: 36992128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Effectiveness of Four Types of COVID-19 Vaccines.
    Abdel-Qader DH; Abdel-Qader H; Silverthorne J; Kongkaew C; Meslamani AZA; Hayajneh W; Alwahadneh AM; Hamadi S; Abu-Qatouseh L; Awad R; Al Nsour M; Alhariri A; Shnewer K; Da'ssan M; Obeidat NM; Nusair KE; Jalamdeh MS; Hawari F; Asad M; AbuRuz S
    Vaccines (Basel); 2023 May; 11(5):. PubMed ID: 37243089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.